Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERAP2 | Q6P179 | 3/20 | 0.64 |
| ▸ | GHSR | Q92847 | 2/20 | 0.55 |
| ▸ | KISS1R | Q969F8 | 13/20 | 0.55 |
| ▸ | IL1RN | P18510 | 2/20 | 0.55 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.55 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.53 |
| ▸ | MMP1 | P03956 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29691762 | 0.94 | ERAP2 (0.70) | ERAP2GHSRIL1RNERAP1MMP1 | |
| SCHEMBL31253136 | 0.91 | ERAP2 (0.55) | ERAP2MMP1 | |
| SCHEMBL30465909 | 0.91 | ERAP2 (0.70) | ERAP2GHSRIL1RNERAP1MMP1 | |
| SCHEMBL27867690 | 0.91 | ERAP2 (0.60) | ERAP2GHSRKISS1RIL1RNERAP1 | |
| SCHEMBL27867688 | 0.91 | ERAP2 (0.60) | ERAP2GHSRKISS1RIL1RNERAP1 | |
| SCHEMBL29486225 | 0.91 | GHSR (0.57) | ERAP2GHSRKISS1R | |
| SCHEMBL31720527 | 0.90 | ERAP2 (0.63) | ERAP2GHSRIL1RNERAP1MMP1 | |
| SCHEMBL31232500 | 0.90 | ERAP2 (0.63) | ERAP2GHSRIL1RNERAP1 | |
| SCHEMBL29874494 | 0.90 | ERAP2 (0.56) | ERAP2GHSRKISS1RUTS2RMMP1 | |
| SCHEMBL29353806 | 0.90 | ERAP2 (0.60) | ERAP2GHSRKISS1RIL1RNERAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368709-A1 | GLP-1 RECEPTOR ANTAGONISTS | NXERA PHARMA UK LTD (GB) | 2025-12-04 | — | — | US | claimed |
| US-12441777-B2 | GLP-1 receptor antagonists | NXERA PHARMA UK LIMITED (GB) | 2025-10-14 | — | — | US | claimed |
| US-20250368709-A1 | GLP-1 RECEPTOR ANTAGONISTS | NXERA PHARMA UK LTD (GB) | 2025-12-04 | — | — | US | disclosed |
| US-12441777-B2 | GLP-1 receptor antagonists | NXERA PHARMA UK LIMITED (GB) | 2025-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250368709-A1 | GLP-1 RECEPTOR ANTAGONISTS | GLP1R, GIPR, GCGR | ERAP2 536/4885GHSR 6/4885KISS1R 119/4885 |
| US-12441777-B2 | GLP-1 receptor antagonists | GLP1R, GIPR, GPR119 | ERAP2 521/4885GHSR 6/4885KISS1R 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.